Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals shares soared nearly 20 percent on over 4.5 million shares traded Tuesday after reporting positive results from a Phase III study of tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder.
Going forward ... (see research report)
Subscribe to News Feeds